Module 4 (a) Flashcards
Cardiovascular Dz Prevention
-Recommendations?
Look at article**
CVD
-Modifiable Risk Factors
- Smoking
- Dyslipidemia
- DMT2
- Increased waist to hip ratios
- Physical inactivity
- Poor diet
- HTN
- Psychosocial stress
ASCVD Risk Assessment
-What is it?
- Estimate a patients initial 10-year ASCVD risk in ages 40-79 yrs old ***
- You can only do LIFETIME risk not 10 year risk outside of the age range
- Low risk (<5%)
- Borderline Risk (5-7.5%)
- Intermediate risk (>/=7.5-20%)
- High risk (>/=20%)
ASCVD
-Risk?
- Most Potent risk factor for ASCVD over age 50 is diabetes
Diabetes T2DM Med Management
-SGLT-2 & GLP-IR
- SGLT-2
- Significant reduction in ASCVD events and HF
- “Flozin” meds - GLP-IR Agonists
- Found to significantly reduce ASCVD events w/ T2DM and high risk
- “utide” meds
Lipids
-Labs to monitor
- Fasting Lipid panel and CMP
- Follow up in 4-12 wks to check adherence and for med changes
- Check yearly once stable
- Check CMP and CK if pt is symptomatic of liver dz or has myalgias
Lipid Labs
-Total cholesterol?
- Total cholesterol below 200 mg/dl is Optimal; High is above 240 mg/dl
Lipid Labs
-LDL-C?
- LDL below 100 mg/dl is Optimal; VERY HIGH is above 190 mg/dl
Treat to the LDL
Lipid Labs
-HDL?
- HDL above 60 is optimal; Very low is below 40
Lipid Labs
-Triglycerides
- Below 150 is Optimal; Very high is above 500
If Triglycerides come back high, question if patient was fasting**
Hypertriglyceridemia
-FIBRATES
- Fasting serum Triglyceride level > 400mg/dl
- FIBRATES decrease triglyceride values by 35-50% and increase HDL levels 5-20%
- NO FIBRATES to pt’s with severe hepatic or renal dysfunction
- Complication risk is Increased when used with Statins
- MONITOR LFT’s to detect and prevent liver damage
Hypertriglyceridemia
-Complications
- HTG is the 3rd most common cause of acute pancreatitis after alcohol and gallstones
- If Triglyceride level is persistently above 886 mg/dl, start drug therapy to lower risk of pancreatitis
Hypertriglyceridemia
-Management
- Statins
- Bile Acid sequestrants
- Nicotinic acid
- Fibric acids
- Cholesterol absorption inhibitors
Hyperlipidemia
-Primary Prevention
- Assess risk factors beginning in childhood
- Age <19 w/ familial hypercholesterolemia = START STATIN
- Age 20-39 = estimate lifetime risk and promote healthy lifestyle
- Consider statin in those w/ family hx of premature ASCVD and LDL-C >/= 160
Hyperlipidemia
-Treatment Guideline (High Intensity)
- Ages 20-75 + LDL-C >/=190 mg/dl = high intensity statin w/out risk assessment
- T2DM >/= 10 yrs, T1DM >/=20 years, renal dz, retinopathy, PVD with ABI <0.9
- High intensity statin w/ aim to lower LDL by 50%
Hyperlipidemia
-Treatment Guideline (Moderate Intensity)
- Ages 40-75 + T2DM = Moderate intensity statin
- Use risk assessment to see if patient needs high intensity statin
Hyperlipidemia
-Treatment Guideline CAD
If a patient has known coronary disease, they need to be on a statin.
Treatment guidelines are for patient w/out known coronary artery disease